Radiopharmaceutical · developed by Lantheus Medical Imaging
[68Ga]-LNTH-2401 is a gallium-68 labeled agent administered to identify newly diagnosed prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07831824 | Phase 2/3 | Prostate Cancer | Recruiting | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Prostate Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →